Please login first

Biomedicines Webinar | Cardiovascular and Metabolic Disease: New Treatments and Future Directions

Part of the MDPI Biomedicines Webinars series
10 Jan 2024, 10:00 (CET)

Cardiovascular Disease, Metabolic Disease, Diabetes, Therapy, Heart Failure, Heart Transplantation
Bookmark event Remove event from bookmarks
Add this event to bookmarks
Event Registration Contact Us

Welcome from the Chair

Dear Attendees,

Welcome to a transformative exploration of the dynamic field of healthcare, where cutting-edge science converges with visionary treatment strategies. I am honored to extend a warm invitation to all passionate minds, industry leaders, and knowledge seekers to the webinar "Cardiovascular and Metabolic Disease: New Treatments and Future Directions".

In an era defined by rapid innovation, we find ourselves at the nexus of unprecedented opportunities to revolutionize the treatment of cardiovascular and metabolic disease. Join us for an insightful journey that unveils the latest breakthroughs, challenges dogma, and illuminates the path toward a healthier future. Our distinguished speakers—true luminaries in their fields—will unveil their visions for the future.

Thank you for your enthusiasm and dedication to pushing the boundaries of medical knowledge. Let us transform the future of healthcare, one breakthrough at a time.

Warm regards,
Alfredo Caturano, Chair,

“Cardiovascular and Metabolic Disease: New Treatments and Future Directions” Webinar

Date: 10 January 2024

Time: 10:00 am CET | 4:00 am EST | 5:00 pm CST Asia

Webinar ID: 838 7843 8645

Webinar Secretariat:

Event Chairs

Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Italy

Alfredo Caturano, MD, graduated in Medicine and Surgery from the Second University of Naples (SUN) in 2016. He achieved a Specialization Degree in Internal Medicine in 2021 at the University of Campania “Luigi Vanvitelli”. His specialization thesis, concerning the impact of glycaemic control on cardiovascular outcomes and mortality in a cohort of patients with type 2 diabetes mellitus in a multifactorial randomized controlled trial, was awarded the 2021 Annapaola Braggio prize by the Italian Society of Diabetology as the best specialization thesis on topics related to insulin resistance. He presently serves as a PhD attendant at the University of Campania “Luigi Vanvitelli”, and has been supported with multiple grants from both Italian and European scientific societies.

Invited Speakers

Pharmacology Laboratory, Department of Medicine, University of Patras, Greece,
School of Medicine, European University Cyprus, Greece

Professor Kyriakos E. Kypreos completed his undergraduate studies at the University of Crete and immediately after received his Ph.D. degree from Boston University Medical School Division of Graduate Medical Sciences. Then, he was trained at the Whitaker Cardiovascular Institute at Boston University Medical Center in the U.S.A (1998-2002) and at Leiden University Medical Center, Department of Human Genetics (2002-2004) in the Netherlands. In 2004 he was appointed as Instructor and in 2006 as Research Assistant Professor in Medicine at Boston University School of Medicine. In 2008, he became Associate Professor of Pharmacology at the Pharmacology laboratory at The University of Patras School of Health Sciences, Department of Medicine, in Greece‚ where in December 2013‚ he was promoted to the rank of full Professor of Pharmacology. Since September 2014, he is also the Director of the Laboratory. He also holds a secondary academic appointment as Visiting Professor at the European University Cyprus, School of Medicine. Prof. Kypreos' research interests focus on the pharmacology of metabolic syndrome with emphasis on the lipid and lipoprotein transport system. Prof. Kypreos has been an EMBO Fellow, a Marie-Curie Fellow and the winner of “Irvine H. Page” Atherosclerosis Research Award, offered by the ATVB council of the American Heart Association. Since Dec 1 2018, he is an elected member of the Executive Committee of the Hellenic Atherosclerosis Society (HAS). From 2016 to 2023, Prof. Kypreos served as vice chairman of the National Pharmacovigilance Committee (EFAR), he also served in the past as member of the Health Technology Assessment (HTA) committee (ΕΑΑΦΑΧ) of the Hellenic Ministry of Health. His most current publication record please refer to PubMed. For updated statistics on his published work please visit google scholar or scopus. Prof. Kypreos' orchid profile may be found at and his LinkedIn profile at

Department of Internal Medicine II, Division of Cardiology, Paracelsus Medical University, Austria

Alexander E. Berezin received an MD degree from the State Medical University, Zaporozhye, Ukraine, in 1992. He earned a PhD degree in the field of Heart Failure at the State Medical University, Zaporozhye, Ukraine in 1994. In 2010, he became a Professor of Medicine, Senior Consultant of Cardiology Unit of Internal Medicine Department at the State Medical University, Zaporozhye, Ukraine. Since 2022, he has worked in the Internal Medicine Department-II, Division of Cardiology, Paracelsus Medical University, Salzburg, Austria. His research interests include the fundamental study of biological markers of cardiovascular, renal, and metabolic diseases, including heart failure, diabetes mellitus, and cardiovascular disease prevention and rehabilitation, especially in the fields of heart failure and coronary artery disease, improving knowledge in vascular biology and regenerative medicine.

Dept. of Internal Medicine (retired Professor), School of Medicine, Federico II University, Italy.

Serafino Fazio MD was born in Naples (Italy) on February 5, 1950. He obtained a scientific high school diploma in June 1968, and graduated in Medicine and Surgery at the University Federico II of Naples, School of Medicine, on December 21, 1974, specializing in internal medicine and cardiology. He worked first as a university researcher and, later, as an associated professor of internal medicine, at the University Federico II of Naples, School of Medicine, from July 1975 to July 2012. He is now retired. Serafino Fazio is the author of more than 170 papers published in prestigious journals. Among these include the New England Journal of Medicine, Nature Medicine, Annals of Internal Medicine, Circulation and the International Journal of Cardiology. He was particularly interested in the interaction between hormones and the heart, heart failure treatment, metabolic syndrome, nutraceutical substances and, recently, in COVID-19 treatment. According to Google Scholar, his h-index is 48. He performed clinical activity in a cardiology department with a coronary care unit from August 1975 to May 1997, then in a department of internal medicine from June 1997 to August 2012. Since June 2016, he has been a freelance physician and independent researcher in the city of Gallipoli. He works as an independent researcher on COVID-19 and its therapeutic possibilities, and on insulin resistance/hyperinsulinemia as an independent risk factor for the development of cardiovascular diseases and its possible therapies. Known languages: Italian (native); English (intermediate).



Time in CET

Dr. Alfredo Caturano (Chair)

Chair Introduction

10:00-10:10 AM

Prof. Dr. Kyriakos E. Kypreos(Speaker 1)

High-Density Lipoprotein: A Guardian Angel or Indifferent Bystander?

10:10 – 10:30 AM

Prof. Alexander E. Berezin (Speaker 2)

The Impact of SGLT2 Inhibitor Dapagliflozin on Adropin Serum Levels in Men and Women with Type 2 Diabetes Mellitus and Chronic Heart Failure

10:30 - 10:50 AM

Prof. Serafino Fazio (Speaker 3)

Insulin Resistance/Hyperinsulinemia: A Too Long Underestimated Cardiovascular Risk Factor

10:50 -11:10 AM


11:10 - 11:25 AM

Closing of Webinar
Alfredo Caturano (Chair)

11:25 - 11:30 AM

Webinar Recording

To view this content, you need to be registered and logged in to Sciforum platform.

Relevant Special Issue

"Cardiovascular and Metabolic Disease: New Treatment and Future Directions—the 3rd Edition"

Edited by Dr. Alfredo Caturano

Deadline for manuscript submissions: 31 May 2024

Sponsors and Partners